TriNetX agreed to link its genomic and proteomic data capabilities with Regeneron under a deal granting exclusive, secure access to de-identified health data covering roughly 300 million individuals. The collaboration is structured to support drug discovery and development workflows using real-world and molecularly anchored datasets. Separately, CellCarta partnered with Pillar Biosciences to provide NGS tumor profiling for oncology clinical trials, aiming to reduce screening friction and failure rates while improving turnaround time and standardized implementation for companion diagnostics. Together, the announcements underline how biopharma is prioritizing integrated data supply—genomics and proteomics plus biomarker panels—both to speed patient matching and to accelerate clinical translation.